Market cap
$313 Mln
Revenue (TTM)
$205 Mln
P/E Ratio
--
P/B Ratio
4.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
46.09
-
EV/EBITDA
-40.9
-
Debt to Equity
0.8
-
Book Value
$--
-
EPS
$-0.9
-
Face value
--
-
Shares outstanding
65,034,552
5 Years Aggregate
CFO
$-94.58 Mln
EBITDA
$-96.00 Mln
Net Profit
$-132.99 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Treace Medical Concepts (TMCI)
| 96.3 | 2.8 | 41.5 | -33.7 | -32.4 | -29.3 | -- |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Treace Medical Concepts (TMCI)
| -67.1 | -41.4 | -44.5 | 23.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Treace Medical Concepts (TMCI)
|
4.8 | 312.8 | 205.3 | -59.5 | -26.2 | -76.8 | -- | 4.7 |
| 62.7 | 8,162.7 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.0 | |
| 15.0 | 10,125.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.8 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.4 | |
| 58.5 | 8,913.0 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 177.5 | 10,637.8 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 15.3 | |
| 101.0 | 6,590.6 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24.2 | 5.0 | |
| 322.2 | 12,649.5 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.3 | 8.3 | |
| 167.6 | 9,458.6 | 785.1 | 41.5 | 9.9 | 2 | 232.8 | 4.6 | |
| 28.9 | 12,007.0 | 6,164.0 | 625.0 | 13.0 | 11.8 | 19.5 | 2.3 |
Shareholding Pattern
View DetailsAbout Treace Medical Concepts (TMCI)
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity,... stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. Read more
-
CEO, Founder & Director
Mr. John T. Treace
-
CEO, Founder & Director
Mr. John T. Treace
-
Headquarters
Ponte Vedra, FL
-
Website
FAQs for Treace Medical Concepts (TMCI)
What is the current share price of Treace Medical Concepts Inc (TMCI) Today?
The share price of Treace Medical Concepts Inc (TMCI) is $4.81 (NASDAQ) as of 04-Sep-2026 16:00 EDT. Treace Medical Concepts Inc (TMCI) has given a return of -32.4% in the last 3 years.
What is the current PB & PE ratio of Treace Medical Concepts Inc (TMCI)?
Since, TTM earnings of Treace Medical Concepts Inc (TMCI) is negative, P/E ratio is not available.
The P/B ratio of Treace Medical Concepts Inc (TMCI) is 4.69 times as on 04-Sep-2026, a 24 premium to its peers’ median range of 3.78 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.65 |
1.79 |
2024 |
-8.32 |
4.11 |
2023 |
-15.88 |
5.70 |
2022 |
-29.83 |
21.10 |
2021 |
-48.63 |
10.74 |
What is the 52 Week High and Low of Treace Medical Concepts Inc (TMCI)?
The 52-week high and low of Treace Medical Concepts Inc (TMCI) are Rs 7.63 and Rs 1.17 as of 08-Sep-2026.
What is the market cap of Treace Medical Concepts Inc (TMCI)?
Treace Medical Concepts Inc (TMCI) has a market capitalisation of $ 313 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Treace Medical Concepts Inc (TMCI)?
Before investing in Treace Medical Concepts Inc (TMCI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.